Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.927 USD | -2.32% | +2.17% | -34.62% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.62% | 144M | |
+8.21% | 115B | |
+12.94% | 107B | |
-13.61% | 22.31B | |
-3.99% | 21.6B | |
-5.76% | 18.23B | |
-39.93% | 17.62B | |
+7.30% | 14.26B | |
+33.58% | 12.37B | |
-28.00% | 8.28B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023